The meta-analysis by Zhou showed that the treatment with SGLT2 inhibitors significantly reduced liver stiffness measurement (LSM) and controlled attenuation parameter (CAP), both of which are validated surrogates for hepatic fibrosis and steatosis. This evidence concerns the gene SLC5A2 and steatosis.